Head-to-head dispatch
NuuVim vs WellMedr
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
Marked down on: There is no month-to-month plan: every rate is billed as one three-month payment
Desk Score
Both molecules, a real brand-name Ozempic and Zepbound lane and an eight-SKU microdose line — advertised from $59 a month, a floor the company's own banner ties to a twelve-month plan and bills every four weeks.
Marked down on: The microdose page headlines "ZERO Side Effects" over a subhead reading "Zero side effct for 70%+ of members" (their typo) — an unqualified claim for a compounded GLP-1, on a page carrying none of the thyroid or compounding warnings the pricing page does
NuuVim takes this head-to-head with the higher Desk Score, 64/100 (C) against 55/100 (C) for WellMedr. WellMedr still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
NuuVim
64/100
C
WellMedr
55/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | NuuVim | WellMedr |
|---|---|---|
| Semaglutide | $79/mo (all doses, 3-mo plan, new patients only, compounded) | From $59/mo (a floor — the banner ties $59/mo to a 12-month plan; billed every 4 weeks) |
| Tirzepatide | $133/mo (all doses, 3-mo plan, new patients only, compounded) | From $99/mo (a floor, flat at every dose; billed every 4 weeks) |
| Coverage | Coverage not published | Not disclosed |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | Readers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing. | Readers shopping the low-dose end who want the dispensing pharmacy and the treating clinicians named, and who will read the twelve-month lock behind the $59 before they start. |
| Desk Score | 64/100C | 55/100C |
The verdict
Desk pick — NuuVimNuuVim takes this head-to-head with the higher Desk Score, 64/100 (C) against 55/100 (C) for WellMedr. WellMedr still holds its ground where its strengths line up with yours.
Choose NuuVim if…
Readers who want low-cost compounded GLP-1s (injection or oral), flat all-dose pricing.
$79/mo (all doses, 3-mo plan, new patients only, compounded) sema · $133/mo (all doses, 3-mo plan, new patients only, compounded) tirz · Coverage not published
Choose WellMedr if…
Readers shopping the low-dose end who want the dispensing pharmacy and the treating clinicians named, and who will read the twelve-month lock behind the $59 before they start.
From $59/mo (a floor — the banner ties $59/mo to a 12-month plan; billed every 4 weeks) sema · From $99/mo (a floor, flat at every dose; billed every 4 weeks) tirz · Not disclosed
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: NuuVim · WellMedr.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- NuuVim vs CoreAge Rx
- WellMedr vs Vaylen
- NuuVim vs Strut Health
- WellMedr vs Ondra Health
- NuuVim vs Invigor Medical
- WellMedr vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.